Screener
Arbutus Biopharma Corporation ABUS Short-Term Investments
Short-Term Investments at other companies
Other financials
Where this comes from
Reported directly by Arbutus Biopharma Corporation in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent.
The source filing: Arbutus Biopharma Corporation’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 7:31 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001447028-26-000021
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $23,706 | $18,008 |
| Investments in marketable securities, current | 71,520 | 73,463 |
| Accounts receivable | 1,312 | 1,447 |
| License receivable from Genevant | 178,741 | — |
| Prepaid expenses and other current assets | 1,732 | 1,538 |
| Total current assets | 277,011 | 94,456 |
ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)
FAQ
- What is Arbutus Biopharma Corporation's short-term investments?
- Arbutus Biopharma Corporation (ABUS) reported short-term investments of $71.52M in Q1 2026.
- How has Arbutus Biopharma Corporation's short-term investments changed year-over-year?
- Arbutus Biopharma Corporation's short-term investments decreased by 5.4% year-over-year, from $75.63M to $71.52M.
- What is the long-term trend for Arbutus Biopharma Corporation's short-term investments?
- Over 5 years (2020 to 2025), Arbutus Biopharma Corporation's short-term investments has grown at a 0.7% compound annual growth rate (CAGR), from $71.02M to $73.46M.
- What does short-term investments mean?
- Marketable securities and other investments with maturities between three months and one year, providing yield above cash while maintaining liquidity.
Ask your AI about Arbutus Biopharma Corporation's short-term investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude